サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1356558

膀胱がん診断市場レポート：2030年までの動向、予測、競合分析

Bladder Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 Pages | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

膀胱がん診断市場レポート：2030年までの動向、予測、競合分析
出版日: 2023年09月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

膀胱がん診断の動向と予測

世界の膀胱がん診断市場は、2024年から2030年までのCAGRが7.8%で、2030年までに推定48億米ドルに達すると予測されます。この市場の主な促進要因は、膀胱関連疾患に対する意識の高まり、老人人口の増加、コンピュータ断層撮影スキャンや磁気共鳴画像のような高度な診断技術に対する需要の高まりです。世界の膀胱がん診断市場の将来は、病院、診療所、がんセンター市場におけるビジネスチャンスによって有望視されています。

膀胱がん診断市場の洞察

Lucintelの予測では、効果的な生検技術や高度な画像診断のために生検が多く使用されていること、経尿道的膀胱腫瘍切除術への嗜好が高まっていることから、予測期間中に生検が最も高い成長を遂げる見込みです。

病院は、膀胱がんの入院患者数の急増と医療専門家の充実した配置により、最大のセグメントであり続けると思われます。

北米は、確立されたヘルスケアインフラの存在、大手生物製剤企業の存在、主要プレイヤーの存在により、予測期間中に最も高い成長が見込まれます。

本レポートでは、以下の11の主要な質問に回答している：

  • Q.1.市場セグメントのうち、最も有望かつ高成長な機会は何か？
  • Q.2.今後成長が加速するセグメントとその理由は？
  • Q.3.今後成長が加速すると思われる地域とその理由は？
  • Q.4.市場力学に影響を与える主な要因は何か？市場における主な課題とビジネスリスクは？
  • Q.5.この市場におけるビジネスリスクと競合の脅威は？
  • Q.6.この市場における新たな動向とその理由は？
  • Q.7.市場における顧客の需要の変化にはどのようなものがありますか？
  • Q.8.この市場における新たな開発と、その開発をリードしている企業は？
  • Q.9.この市場における主要企業は？主要企業は事業成長のためにどのような戦略的取り組みを進めているのか？
  • Q.10.この市場における競合製品にはどのようなものがあり、材料や製品の代替による市場シェア低下の脅威はどの程度ありますか？
  • Q.11.過去5年間にどのようなM&Aが行われ、業界にどのような影響を与えましたか？

目次

第1章 エグゼクティブサマリー

第2章 世界の膀胱がん診断市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の膀胱がん診断市場動向（2018～2023年）と予測（2024～2030年）
  • 検査タイプ別の世界の膀胱がん診断市場
    • 尿検査
    • 膀胱鏡検査
    • 生検
    • 画像検査
  • がんの種類別の世界の膀胱がん診断市場
    • 移行上皮性膀胱がん
    • 膀胱扁平上皮がん
    • その他
  • 最終用途産業別の世界の膀胱がん診断市場
    • 病院
    • クリニック
    • がんセンター
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の膀胱がん診断市場
  • 北米の膀胱がん診断市場
  • 欧州の膀胱がん診断市場
  • アジア太平洋膀胱がん診断市場
  • その他地域膀胱がん診断市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 検査タイプ別の世界の膀胱がん診断市場の成長機会
    • がんの種類別の世界の膀胱がん診断市場の成長機会
    • 最終用途産業別の世界の膀胱がん診断市場の成長機会
    • 世界の膀胱がん診断市場地域の成長機会
  • 世界の膀胱がん診断市場の新たな動向
    • 新製品の開発
    • 世界の膀胱がん診断市場の能力拡大
    • 世界の膀胱がん診断市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Ameritech Diagnostic Reagent
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hofmann-La Roche
  • GlaxoSmithKline
  • Novartis International
  • Pfizer
  • Abbott
  • Endo Pharmaceuticals
  • Johnson & Johnson
目次

Bladder Cancer Diagnostic Trends and Forecast

The future of the global bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets. The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.

A more than 150-page report is developed to help in your business decisions.

Bladder Cancer Diagnostic by Segment

The study includes a forecast for the global bladder cancer diagnostic by test type, cancer type, end use industry, technology, and region.

Bladder Cancer Diagnostic Market by Test Type [Shipment Analysis by Value from 2018 to 2030]:

  • Urine Lab Tests
  • Cystoscopy
  • Biopsy
  • Imaging Tests

Bladder Cancer Diagnostic Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Transitional Cell Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Others

Bladder Cancer Diagnostic Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Clinics
  • Cancer Centers
  • Others

Bladder Cancer Diagnostic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Bladder Cancer Diagnostic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bladder cancer diagnostic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bladder cancer diagnostic companies profiled in this report include-

  • Ameritech Diagnostic Reagent
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hofmann-La Roche
  • Glaxosmithkline
  • Novartis International
  • Pfizer
  • Abbott
  • Endo Pharmaceuticals
  • Johnson & Johnson

Bladder Cancer Diagnostic Market Insights

Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.

Hospital will remain the largest segment due to surge in bladder cancer hospitalizations and substantial availability of healthcare experts in this setting.

North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.

Features of the Global Bladder Cancer Diagnostic Market

Market Size Estimates: Bladder cancer diagnostic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Bladder cancer diagnostic market size by test type, cancer type, end use industry, and region. in terms of value ($B).

Regional Analysis: Bladder cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different test types, cancer typse, end use industries, and region.s for the bladder cancer diagnostic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bladder cancer diagnostic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the bladder cancer diagnostic market size?

Answer: The global bladder cancer diagnostic market is expected to reach an estimated $4.8 billion by 2030.

Q.2. What is the growth forecast for bladder cancer diagnostic market?

Answer: The global bladder cancer diagnostic market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the bladder cancer diagnostic market?

Answer: The major drivers for this market are growing awareness of bladder related diseases, increasing number of geriatric popuation, and rising demand for advanced diagnostic technologies like computed tomography scan and magnetic resonance imaging.

Q.4. What are the major segments for bladder cancer diagnostic market?

Answer: The future of the bladder cancer diagnostic market looks promising with opportunities in the hospital, clinic, and cancer center markets.

Q.5. Who are the key bladder cancer diagnostic market companies?

Answer: Some of the key bladder cancer diagnostic companies are as follows:

  • Ameritech Diagnostic Reagent
  • Bristol-Myers Squibb
  • Eli Lilly
  • F. Hofmann-La Roche
  • GlaxoSmithKline
  • Novartis International
  • Pfizer
  • Abbott
  • Endo Pharmaceuticals
  • Johnson & Johnson

Q.6. Which bladder cancer diagnostic market segment will be the largest in future?

Answer: Lucintel forecasts that biopsy is expected to witness highest growth over the forecast period due to its substantial use for effective biopsy technique and advanced imaging and rising preference for transurethral resection of bladder tumor approach.

Q.7. In bladder cancer diagnostic market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to exisitence of well-established healthcare infrastructure, availability of major biologics companies, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the bladder cancer diagnostic market by test type (urine lab tests, cystoscopy, biopsy, and imaging test), material (transitional cell bladder cancer, squamous cell bladder cancer, and others), end use industry (hospitals, clinics, cancer center, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Bladder Cancer Diagnostic Market: Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Bladder Cancer Diagnostic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Bladder Cancer Diagnostic Market by Test Type
    • 3.3.1: Urine Lab Tests
    • 3.3.2: Cystoscopy
    • 3.3.3: Biopsy
    • 3.3.4: Imaging Tests
  • 3.4: Global Bladder Cancer Diagnostic Market by Cancer Type
    • 3.4.1: Transitional Cell Bladder Cancer
    • 3.4.2: Squamous Cell Bladder Cancer
    • 3.4.3: Others
  • 3.5: Global Bladder Cancer Diagnostic Market by End Use Industry
    • 3.5.1: Hospitals
    • 3.5.2: Clinics
    • 3.5.3: Cancer Centers
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Bladder Cancer Diagnostic Market by Region
  • 4.2: North American Bladder Cancer Diagnostic Market
    • 4.2.1: North American Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.2.2: North American Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
  • 4.3: European Bladder Cancer Diagnostic Market
    • 4.3.1: European Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.3.2: European Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
  • 4.4: APAC Bladder Cancer Diagnostic Market
    • 4.4.1: APAC Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.4.2: APAC Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others
  • 4.5: ROW Bladder Cancer Diagnostic Market
    • 4.5.1: ROW Bladder Cancer Diagnostic Market by Test Type: Urine Lab Tests, Cystoscopy, Biopsy, and Imaging Tests
    • 4.5.2: ROW Bladder Cancer Diagnostic Market by End Use Industry: Hospitals, Clinics, Cancer Center, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by Test Type
    • 6.1.2: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Bladder Cancer Diagnostic Market by End Use Industry
    • 6.1.4: Growth Opportunities for the Global Bladder Cancer Diagnostic Market Region
  • 6.2: Emerging Trends in the Global Bladder Cancer Diagnostic Market
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Bladder Cancer Diagnostic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bladder Cancer Diagnostic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Ameritech Diagnostic Reagent
  • 7.2: Bristol-Myers Squibb
  • 7.3: Eli Lilly
  • 7.4: F. Hofmann-La Roche
  • 7.5: GlaxoSmithKline
  • 7.6: Novartis International
  • 7.7: Pfizer
  • 7.8: Abbott
  • 7.9: Endo Pharmaceuticals
  • 7.10: Johnson & Johnson